drugset

drugset / Trial / NCT00150605

Safety of SPD417 Combined With Other Psychotropic Medications in the Treatment of Bipolar I Disorder

NCT00150605 ↗

Phase 3 Completed 50 enrolled Validus Pharmaceuticals

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety of SPD417 when given with other psychotropic medications to treat bipolar I disorder.

Timeline

Start: 2005-02
Primary completion: —
Completion: 2005-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Carbamazepine	Small molecule	—	—

Indications